Accumulus Technologies

Heading to the #CASSS CMC Strategy Forum North America in Ottawa? As regulatory modernization continues to advance, we're seeing a clear shift across the industry from discussing what's possible to implementing new ways of working. Organizations are increasingly looking for practical approaches for scalable collaborative reliance, modern CMC lifecycle management, and digital regulatory execution. Our team will be there, and we'd love to connect! Join Francisco Nogueira, CEO of Accumulus Technologies, and Dominique Lagrave, Chief Regulatory Officer, to discuss how shared digital infrastructure is helping regulators and industry move from vision to proven operational execution. Don't miss Francisco's presentation during Workshop I: Operationalizing Modern CMC Lifecycle Management: The Digital Infrastructure Behind Collaborative Regulatory Execution. The session will explore: • How digital infrastructure is enabling modern CMC lifecycle management • Real-world customer case studies and demonstrated outcomes • Practical approaches to collaborative regulatory execution that support greater reliance, simultaneous collaboration, and more efficient post-approval change management If you're attending CASSS, make sure to connect with our team. We'd love to hear about your priorities! #CMC #RegulatoryAffairs #LifecycleManagement #CMCStrategy #RegulatoryModernization #GlobalHarmonization #DigitalTransformation #Biopharma #AccumulusTechnologies

The Accumulus Platform was developed in response to a growing recognition that regulatory systems require digital transformation to keep pace with modern biomedical innovation. Accumulus Technologies is proud to support this transformation and grateful to our customers for highlighting how the Accumulus platform is helping modernize regulatory collaboration. Real-world experience continues to demonstrate what's possible when regulators and industry collaborate through shared digital infrastructure. Today, the Platform connects more than 75 health authorities across six continents, collectively serving approximately 4.6 billion people—more than half of the global population. Together, we're enabling a more connected regulatory ecosystem: one that has demonstrated up to 90% faster global approvals and 75% efficiency gains, helping sponsors and regulators bring innovative medicines to patients more efficiently. Whether you're launching a new therapy, expanding into new markets, or managing post-approval changes, the Accumulus platform helps organizations execute a faster, more connected global submission strategy. Learn more here: https://lnkd.in/euTPW_q9 #accumulusplatform #elililly #regulatoryinnovation #patientsfirst #digitaltransformation

What if cancer patients could gain access to innovative medicines weeks, months, even years sooner? That's the ambition behind a first-of-its-kind collaboration between Chile's Public Health Institute (#ISP), a global biopharmaceutical company, and Accumulus Technologies. Marking a significant milestone for patients, regulators, and the future of global regulatory collaboration, we're proud to support a series of regulatory firsts: - Chile's first fully digital review of an initial market application through a dedicated cloud platform - The first time a novel oncology therapy will be reviewed in Chile through a digital eCTD-based dossier and fully digital review process What makes this initiative particularly meaningful is how it began. Following participation in previous reliance submissions, ISP asked a simple but powerful question: How can we modernize regulatory review, strengthen collaboration, and help patients access important medicines sooner? To answer that question, ISP partnered with Accumulus Technologies to identify an existing platform participant willing to pioneer a new model for regulatory submission and review. One of Accumulus Technologies' global biopharmaceutical customers stepped forward, becoming the inaugural applicant in this groundbreaking initiative. The objective is clear: bring important therapies to patients faster by: - Leveraging existing eCTD standards without requiring local dossier adaptations - Reusing information and assessments already generated by trusted reference authorities - Enabling  smarter, modern regulatory collaboration For patients waiting for new oncology treatments, every day matters. This initiative is about more than a single submission. It demonstrates how regulators, industry, and digital infrastructure can work together in new ways to advance information equity, strengthen regulatory capacity, and create a scalable model for faster access to medicines worldwide. Importantly, we believe this initiative has the potential to serve as a model for other regulatory agencies around the world, as Chile's leadership inspires other health authorities to pursue similar approaches in support of faster patient access and more efficient regulatory decision-making. We're honored to support ISP in this trailblazing effort and look forward to seeing the impact it will have for patients both in Chile and around the world. #PatientAccess #RegulatoryInnovation #DigitalTransformation #GlobalHealth #RegulatoryAffairs #Accumulus #Chile #healthequity

As regulatory modernization accelerates around the world, the conversation is shifting from vision to execution, from what's possible to what's already operationally achievable. We're pleased to share that our CEO, Francisco Nogueira, will be speaking at the CASSS – Sharing Science Solutions CMC Strategy Forum North America, joining industry and regulatory leaders during Workshop I: Regulatory Modernization and Global Harmonization. During the presentation, "Operationalizing Modern CMC Lifecycle Management: The Digital Infrastructure Behind Collaborative Regulatory Execution", Francisco will explore: - How digital infrastructure is enabling the practical execution of modern CMC lifecycle management: - Real-world customer case studies and proven outcomes - How technology is helping transform regulatory modernization into scalable operational practice supporting greater reliance, simultaneous collaboration, and more efficient CMC lifecycle management. The session also features perspectives from Health Canada on modernization of CMC review and Amgen on near-concurrent collaborative reliance, providing attendees with a unique opportunity to hear from regulators, industry, and technology leaders working to advance the future of global regulatory collaboration. Are you attending the CMC Strategy Forum North America? Let us know! We look forward to connecting. #CMC #RegulatoryAffairs #LifecycleManagement #CMCStrategy #RegulatoryModernization #GlobalHarmonization #ICH #DigitalTransformation #Biopharma #AccumulusTechnologies

Security and compliance are strategic enablers of digital transformation. For our customers who are modernizing regulatory collaboration, trust is just as important as innovation. Cloud-based collaboration between sponsors and health authorities depends on confidence that sensitive regulatory information is protected through robust governance, independent validation, and continuously monitored controls. That's why independent certifications matter and why we are proud to have achieved SOC 2 Type 2 Attestation, HITRUST i1 Certification, ISO 27001 Certification for the Accumulus Platform. Together, they provide independent verification that the platform's security, risk management, and information protection practices have been assessed against globally recognized standards. For our customers, this translates into tangible benefits: ➡️ Greater confidence when exchanging regulatory information ➡️More efficient security and vendor due diligence reviews ➡️A stronger foundation for adopting cloud-based regulatory collaboration ➡️Assurance that security practices continue to evolve alongside regulatory expectations At Accumulus, security is designed into the infrastructure from the start because modernizing global regulatory collaboration requires a proven digital infrastructure that enables organizations to collaborate with confidence. Learn more here: https://lnkd.in/ge3RtAwb #accumulusplatform #security #compliance #lifesciences #regulatorycollaboration

"What is Accumulus Direct Connect for Veeva RIM? Does it require a lengthy implementation?" Our Chief Product & Technology Officer, Chanille Juneau, explains it simply: "The Accumulus direct connect for VeevaRIM is a direct connection between your Veeva RIM and the Accumulus platform. Direct connect means there is no custom development work required. So your tech team, your IT team, your regulatory team does not have to build anything. You don't have to configure a middleware layer from scratch. You don't need to engage an outside systems integrator or a lengthy implementation. It's a connection that's purpose-built and ready to deploy." For many organizations, that's an important distinction. Too often, connecting systems means months of planning and custom development before teams can realize any value. The Accumulus Direct Connect for Veeva RIM takes a different approach. It provides a purpose-built connection between Veeva RIM and the Accumulus platform, so that you can connect your RIM directly to regulators around the world. The Direct Connect extends the Accumulus platform into your existing technology stack, making the Accumulus global regulatory network accessible without switching systems or duplicating effort. Learn more about how you can turn your system of record into a live global collaboration channel: https://lnkd.in/e5uZvRP6 #RegulatoryAffairs #VeevaRIM #LifeSciences #DigitalTransformation #RegulatoryTechnology #AccumulusTechnologies

What if you could accelerate your global regulatory approval timeline by 90%? What would that make possible for your organization? For most life sciences companies, the answers are immediate: accelerated revenue, extended patent value, lower operational costs, greater portfolio velocity, and most importantly: faster patient access to innovative therapies. These aren't aspirational goals. They're business outcomes that are often left unrealized because the infrastructure supporting global regulatory exchange was built for a different era. For decades, global approvals have followed a sequential "wave model." Sponsors submit to one health authority, wait for review, respond to questions, and only then move to the next market. It's a document-centric process that requires the same work to be repeated across countries, creating unnecessary duplication, delays, and complexity. While this approach reflected the technological constraints of the past, it no longer reflects what's possible today. The consequences are significant. Every duplicated submission, every asynchronous exchange, and every market operating in isolation contributes to longer approval timelines, increased operational burden, compressed patent value, and reduced lifetime revenue. But beyond the business impact lies an even more important consequence: patients around the world wait longer to access therapies that could improve, or even save, their lives. The ecosystem has made meaningful progress with initiatives like regulatory reliance and collaborative review pathways. Yet these models cannot deliver their full potential without the digital infrastructure needed to support secure, real-time collaboration between industry and regulators at scale. That's why the future isn't about making the existing model slightly more efficient. It's about replacing it with one designed for today's global regulatory environment. At Accumulus, we're enabling that shift with a networked environment of over 75+ regulatory agencies across six continents. Rather than relying on sequential submissions and document exchanges, organizations can submit simultaneously across markets and collaborate with regulators in real time through a shared, secure environment. The results our customers are seeing are compelling: up to 90% faster global approvals, millions in savings per submission, up to 75% greater operational efficiency, and, most importantly, patients gaining access to therapies years sooner. Ready to learn more about what is possible for your organization? Check out this video: https://lnkd.in/euTPW_q9 or reach out today to book a meeting: https://lnkd.in/eqQDdDJu #LifeSciences #RegulatoryAffairs #DigitalTransformation #Pharma #Biotech #PatientAccess #HealthcareInnovation

"Is the technology ready?" "What about information security?" These are questions we still hear in conversations about modernizing regulatory information exchange. But as Michael Abernathy , Associate Vice President, Digital Transformation at #Amgen shared, the technology is already here, and the security is proven. Mike's advice to peers considering the Accumulus platform: ➡️ Don't be afraid to make the change. ➡️ Move beyond questioning whether the technology exists and focus on the value it delivers. ➡️ Trust that the work around security, privacy, and compliance has been done. And, the proof is in the adoption. Since launching globally in 2024, the platform has expanded to 75 countries across six continents. With #SOC2Type2 Attestation, #HITRUSTi1 Certification, and #ISO27001 Certification for the Accumulus platform our customers have verified assurance of the Platform’s security posture. The momentum is clear: customers and regulators are increasingly turning to Accumulus to enable more efficient, secure, and collaborative regulatory information exchange. Most importantly, this transformation is about accelerating access to therapies and ultimately benefiting patients. 🎧 Listen to the full audio clip to hear why Mike believes now is the time to take the leap. Ready to find out more? Book a meeting with a member of team today: https://lnkd.in/eqQDdDJu #RegulatoryAffairs #LifeSciences #DigitalTransformation #RegulatoryOperations #Innovation #PatientsFirst #AccumulusPlatform

That’s a wrap on #DIA2026! As always, it was great to be among so many leaders across the life sciences and regulatory ecosystem. One theme came through consistently in conversations, presentations, and meetings alike: both industry and regulators are actively looking for ways to accelerate, innovate, and modernize regulatory collaboration. The shared pressures of acceleration, sustainability, complexity, and transformation are creating global momentum toward more efficient regulatory pathways. Yet, when it comes to regulatory information exchange, progress has often been limited by something much more fundamental: digital infrastructure. Perhaps the most important shift is that technology is no longer the barrier. The conversation has moved from whether it can be done to how we collectively scale adoption and realize the full value of real-time regulatory collaboration. The networked approach to regulatory exchange that Accumulus offers today, enables information to move securely and efficiently, supporting regulatory interactions and exchange across the entire drug development lifecycle. The specific use cases may differ, but the underlying challenge remains the same: information needs to move. And wherever information needs to move, there is an opportunity to remove friction. One of the most encouraging takeaways from DIA was the growing alignment around this challenge. Organizations across the ecosystem increasingly recognize that scientific innovation reaching patients faster depends not only on breakthrough science, but also on modernizing how regulatory information is exchanged. Thank you to everyone who presented, joined the discussion, shared perspectives, and contributed to the ongoing conversation. The momentum is real. The infrastructure exists. The security is proven. Now, the opportunity ahead is to work together to remove friction and help scientific innovation reach patients at the speed they deserve. #RegulatoryInnovation #RegulatoryAffairs #LifeSciences #DigitalTransformation #RegulatoryCollaboration #RegulatoryExcellence